Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $173.07

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $173.07.

A number of research firms have commented on JAZZ. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price on the stock. Piper Sandler lowered their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Janney Montgomery Scott LLC lifted its position in Jazz Pharmaceuticals by 48.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 10,949 shares of the specialty pharmaceutical company’s stock valued at $1,347,000 after purchasing an additional 3,591 shares during the period. UBS Group AG lifted its holdings in shares of Jazz Pharmaceuticals by 18.4% in the 4th quarter. UBS Group AG now owns 172,947 shares of the specialty pharmaceutical company’s stock valued at $21,272,000 after buying an additional 26,844 shares during the period. Assetmark Inc. boosted its stake in shares of Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares during the last quarter. Cape Investment Advisory Inc. grew its holdings in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares during the period. Finally, Hsbc Holdings PLC raised its position in Jazz Pharmaceuticals by 2,454.2% during the fourth quarter. Hsbc Holdings PLC now owns 49,117 shares of the specialty pharmaceutical company’s stock valued at $5,993,000 after acquiring an additional 47,194 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $110.93 on Wednesday. The company has a market capitalization of $7.00 billion, a P/E ratio of 22.87, a P/E/G ratio of 1.36 and a beta of 0.57. The company’s 50-day simple moving average is $111.02 and its two-hundred day simple moving average is $110.79. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. As a group, equities analysts anticipate that Jazz Pharmaceuticals will post 16.03 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.